Welcome to our dedicated page for NUGEN MEDICAL DEVICES news (Ticker: NGMDF), a resource for investors and traders seeking the latest updates and insights on NUGEN MEDICAL DEVICES stock.
NuGen Medical Devices Inc. develops needle-free devices for subcutaneous drug delivery, centered on the InsuJet™ system for insulin administration and related consumables. Company news commonly covers commercialization of InsuJet and EziAutoJector® through distributors and pharmacy channels, product availability in markets such as France and the United Kingdom, and medical-device regulatory updates tied to national approvals and licensing.
NuGen updates also include research and development for prefilled and cartridge-based needle-free injection formats, patent activity for Ready-to-Fill COP/COC nozzles and the Prefilled Nozzle platform, annual financial results, and governance changes involving financial reporting functions.
Summary not available.
NuGen Medical Devices Inc. has closed the first tranche of a non-brokered private placement, issuing 2,500,000 units at $0.05 each, raising $125,000. Each unit consists of one common share and a warrant, allowing purchase of additional shares at the same price for 60 months. Proceeds will support general working capital. The offering is subject to regulatory approvals, with potential for further financing up to $2,875,000 by January 23, 2023. The company also granted 2,000,000 options to a consultant, exercisable at $0.05 for five years.
NuGen Medical Devices Inc. (TSXV:NGMD)(OTCQB:NGMDF) announces the departure of Michael Wright as President and CEO, effective immediately. He will continue as a director and shareholder, aiding in the transition. Karen Dunlap is appointed as Interim Chief Customer Officer and Derek Lindsay as Interim CEO. Both bring extensive experience in medical technology and business management. The company is restructuring to expedite development and plans to share a revised strategic plan with stakeholders soon. The Board believes these changes will enhance the reach of InsuJet, the company’s needle-free diabetes product.
NuGen Medical Devices has officially launched its InsuJet™ needle-free injection devices in Canada during the 2022 Diabetes Canada/CSEM Professional Conference. Partnering with Sol-Millennium Medical Group, NuGen received a purchase order for 250 InsuJet™ devices, part of a commitment for 750 starter kits in 2022. Future agreements include a total of 14,250 devices over 2.5 years. Each device is estimated to generate approximately CDN$650 in revenue. The InsuJet™ aims to reduce healthcare costs and environmental impact by replacing traditional needles.
Summary not available.
NuGen Medical Devices (TSXV:NGMD)(OTCQB:NGMDF) has appointed Erik Emerson to its Advisory Board. With over 20 years of experience in pharmaceuticals and biotechnology, Emerson has held leadership roles at various organizations, including Mezzion Pharmaceuticals and Gilead. He has a proven track record in commercialization and product launches, notably with the launch of Letairis for pulmonary hypertension. NuGen continues to develop needle-free delivery technologies aimed at improving healthcare outcomes across multiple fields, including diabetes and veterinary medicine.
NuGen Medical Devices Inc. (TSXV:NGMD) (OTCQB:NGMDF) announced plans to file for a new patent in the United States, Europe, and China. This patent aims to protect its needle-free injection device's refill design, enhancing safety and usability for insulin delivery. Initially patented in the Netherlands in October 2021, the new coverage targets key markets for insulin therapy. CEO Michael Wright emphasized that integrating the medicine vial into the device simplifies the injection process, benefiting chronic patients who require frequent injections.
NuGen Medical Devices has received approval from the TSX Venture Exchange to extend the expiry date and reduce the exercise price of 7,500,000 common share purchase warrants. The expiry date is extended by 12 months to September 30, 2023, and the exercise price is reduced from $0.70 to $0.40.
Additionally, the company’s private placement of 10% unsecured convertible debentures totaling $740,000 has received final acceptance, with no additional proceeds raised.
NuGen Medical Devices (TSXV:NGMD)(OTCQB:NGMDF) announced the appointment of Greg Gironda to its Advisory Board on September 16, 2022. With over 30 years in the pharmaceutical and biotechnology sectors, Gironda has extensive experience in needle-free technology and strategic planning. Previously, he played a pivotal role at EMD Serono, where he successfully launched the cool.click needle-free device alongside the Saizen growth hormone, increasing its market share significantly. This appointment demonstrates NuGen's commitment to enhancing its advisory team for developing innovative needle-free solutions.
NuGen Medical Devices Inc. has announced that its common shares received DTC full-service eligibility effective September 9, 2022. This milestone enhances the accessibility of its shares for U.S. investors, as they recently began trading on the OTCQB under the symbol NGMDF. DTC eligibility facilitates electronic clearing and settlement of transfers, marking a significant step in the company's growth strategy. NuGen specializes in needle-free technologies for medical delivery, with products like InsuJet™ and PetJet™, targeting diabetes and veterinary medicine.